Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02043847 · ClinicalTrials.gov registry record · Phase 1
TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)
A Phase 1 study of Multiple Myeloma, Relapsed and Multiple Myeloma, Refractory to Standard Treatment, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT02043847: Completed Phase 1 study of Multiple Myeloma, Relapsed and Multiple Myeloma, Refractory to Standard Treatment, sponsored by University of Illinois at Chicago.
NCT02043847 is a Phase 1 study of Multiple Myeloma, Relapsed and Multiple Myeloma, Refractory to Standard Treatment that has completed, run by University of Illinois at Chicago. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02043847, a Phase 1 study of Multiple Myeloma, Relapsed and Multiple Myeloma, Refractory to Standard Treatment, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
In this phase I trial, patients with relapsed or refractory multiple myeloma will receive standard autologous stem cell transplant conditioned with high dose melphalan. In addition to Melphalan, the conditioning will include targeted total marrow irradiation (TMI). This is a conventional 3+3 phase I trial with increasing doses of TMI from minimum 3Gy to Maximum 9Gy.
Primary Outcome
Assessing MTD of TMI of 3Gy, 6Gy and 9Gy
Conditions Studied
Interventions
- DRUG Melphalan
- RADIATION Total Marrow Irradiation
- DRUG Filgrastim (G-CSF)
- PROCEDURE Autologous transplant
Study Locations (1)
Illinois
- University of Illinois Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-01-14 |
| Est. Completion | 2016-09-14 |
| Phase | Phase 1 |
What the finished NCT02043847 record still lists
NCT02043847 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Multiple Myeloma, Relapsed appearing as the primary indexed condition, and to 4 interventions - of which Melphalan is the first listed.
NCT02043847 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT02043847 about?
NCT02043847 is a clinical study titled "TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)". In this phase I trial, patients with relapsed or refractory multiple myeloma will receive standard autologous stem cell transplant conditioned with high dose melphalan. In addition to Melphalan, the conditioning will include targeted total marrow irradiation (TMI). This is a conventional 3+3 phase I...
What is the current status of trial NCT02043847?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2014-01-14. Estimated completion is 2016-09-14.
What conditions does trial NCT02043847 study?
This clinical trial studies the following conditions: Multiple Myeloma, Relapsed, Multiple Myeloma, Refractory to Standard Treatment.
What interventions are being tested in trial NCT02043847?
The interventions under investigation include: Melphalan (DRUG), Total Marrow Irradiation (RADIATION), Filgrastim (G-CSF) (DRUG), Autologous transplant (PROCEDURE).
Who is sponsoring clinical trial NCT02043847?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02043847 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02043847's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI